ABCL vs. DCPH, COLL, OCUL, XNCR, PRTA, KNSA, IRWD, MIRM, PCRX, and CNTA
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Deciphera Pharmaceuticals (DCPH), Collegium Pharmaceutical (COLL), Ocular Therapeutix (OCUL), Xencor (XNCR), Prothena (PRTA), Kiniksa Pharmaceuticals (KNSA), Ironwood Pharmaceuticals (IRWD), Mirum Pharmaceuticals (MIRM), Pacira BioSciences (PCRX), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
Deciphera Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
AbCellera Biologics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. AbCellera Biologics is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Deciphera Pharmaceuticals has a net margin of -119.33% compared to Deciphera Pharmaceuticals' net margin of -384.99%. Deciphera Pharmaceuticals' return on equity of -12.36% beat AbCellera Biologics' return on equity.
71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by insiders. Comparatively, 32.5% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Deciphera Pharmaceuticals received 270 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.92% of users gave AbCellera Biologics an outperform vote while only 65.71% of users gave Deciphera Pharmaceuticals an outperform vote.
Deciphera Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 61.63%. AbCellera Biologics has a consensus target price of $15.86, suggesting a potential upside of 305.55%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Deciphera Pharmaceuticals.
In the previous week, AbCellera Biologics had 1 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 2 mentions for AbCellera Biologics and 1 mentions for Deciphera Pharmaceuticals. AbCellera Biologics' average media sentiment score of 1.94 beat Deciphera Pharmaceuticals' score of -0.49 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the media.
Summary
AbCellera Biologics beats Deciphera Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
